2. Clinical Bioinformatics: the need for CBAS and SCBC in Applied Sciences? Dr James Mah MBBS(Lon), BSc(Hons,Lon). Chair, CBAS 2009 Singapore Email: tutorsgsg@yahoo.com.sg

3. Clinical Bioinformatics The use of informatics tools and techniques to study and analyse biomedical and genetic data Involves the development of new tools and algorithms to solve biomedical issues Involves new discovery of biomedical knowledge and know how Covers and overlaps with many disciplines and fields in applied sciences Clinical/biomedical example……..

4. CLINICAL BIOINFORMATICS New methods to rapidly and conveniently screen any genetic variant -probability of association with disease risk -probability of treatment outcome

5. The Clinical Bioinformatics Cycle Personalised Medicine Prevention Cure Results? Clinical Bioinformatics (NEW!) DISEASE DRUG (outcome) CANCER RISK PREDICTION TREATMENT OUTCOMES eg TOXICITY HEALTH DEATH (Survival outcome) Egs

6. CASE STUDY 1 – DRUG TREATMENT OUTCOME MODEL a)Study in European-American population (Rieder et al 2005) Gene VKORC1(Vitamin K epoxide reductase complex 1) story

7. b)Study in Asian population (Lee SC et al 2006)

8. CASE STUDY 2 – SURVIVAL OUTCOME MODEL THE GEMCITABINE NON-SMALL CELL LUNG CANCER STORY

9. POTENTIAL USES OF NEW BIOMEDICAL IMAGING TOOLS Screening For suspicious lesions -population screening Eg for breast cancer detection -epidemiological studies -risk stratification – cancer prevention, treatment programmes

10. 1st Clinical Bioinformatics Symposium on Applied Sciences (CBAS) 2009 Promote awareness of Clinical Bioinformatics and its applications in biomedical sciences and healthcare Sharing of views by renowned speakers invited to tackle complex and diverse topics in Clinical Bioinformatics Networking session and SCBC to allow participants to showcase their work to foster inter-disciplinary collaborations Help foster the Clinical Bioinformatics Cycle

11. TIME CBAS PROGRAMME SCHEDULE 8:30 AM Registration 9:00 AM CBAS Opening by Chair, JAMES MAH TITLE:Clinical Bioinformatics: the need for CBAS and SCBS in Applied Sciences? 9:20 AM Keynote Plenary: WONG TIEN YIN TITLE: Translational research and Bioinformatics in Singapore: advances, breakthroughs and initiatives- a clinical prospective” 10:15 AM Special Q&A 10:30 AM Morning Tea Break 11:00 AM Plenary 2: SU YI TITLE: Biomedical modelling with clinical applications 11:30 AM First Singapore Clinical Bioinformatics Consortium Meeting 12:30 PM Lunch Break 1:20 PM 1:30 PM Introduction to Afternoon session by Chair, JAMES MAH Plenary 3:WAYNE MITCHELL TITLE: Translational research and drug discovery:can bioinformatics help? 2:00 PM Plenary 4: LEE HWEE KUAN TITLE: Computer vision and pattern discovery for bioimages: An emerging field in bioinformatics 2:30 PM Plenary 5: CAROLINE LEE TITLE: Pharmacogenomics and personalized medicine- advances and possible roles of bioinformatics 3:00 PM Sponsor Talk: Chris Molloy, VP Corporate Development, ID Business Solutions TITLE: Translational Medicine and Biomarker discovery: an informatics issue 3:30 PM Afternoon Tea Break 4:00 PM Plenary 6: LUN KWOK CHAN TITLE: Medical Informatics: past, present and future 4:30 PM Q&A/Networking/Collaboration presentations II 5:20 PM Plenary panel discussion: Clinical Bioinformatics:Present and Future 5:45 PM CBAS Closing remarks

12. The Singapore Clinical Bioinformatics Consortium (SCBC) Part of CBAS to continue inertia and initiative Seek representatives from each institution to strengthen ties and build up strong links for collaboration in the field of Clinical Bioinformatics Potential aims would be to initiate key or core project areas with potential for development both locally as well as regionally

13. The Singapore Clinical Bioinformatics Consortium (SCBC) Tie-ups with industry and pharmaceutical companies are also encouraged Invitation to be part of this exciting Consortium as committee members to spearhead and drive new clinical bioinformatics projects both regionally and internationally

14. The Singapore Clinical Bioinformatics Consortium (SCBC) Invitation for contribution in but not limited to: -Biomedical Imaging -Translational Research Eg Bench-to-bedside or personalized medicine -Genomics Eg functional annotation of genetic variants with respect to complex/clinical diseases -Drug discovery Eg novel drug target identification and discovery

15. Acknowledgements Dr Victor Tong and InCoB 2009 committee A*STAR All our sponsors and dedicated supporters Distinguished speakers Dedicated CBAS 2009 organising committee: Tze Hau, Meng Ling, Luke, Winnie, all volunteers Delegates and attendees All those indirectly or directly made this event possible